ADA 2026 Experts Clash Over 15% GLP-1 Weight Loss and Muscle Risk

1 articles · Updated · Medscape · Jul 24

ADA 2026 speakers split on whether muscle loss during GLP-1-driven weight loss is clinically worrisome, with Samuel Klein arguing current evidence shows no clear frailty or sarcopenia signal.
Studies of patients losing at least 15% of body weight show lean mass made up about 25% of tirzepatide-related loss and 39% with semaglutide, figures Klein said fall within normal ranges for weight loss and often accompany better physical function.
Eric Ravussin said the bigger concern is not typical trial participants but higher-risk groups—older adults, menopausal women and people with sarcopenic obesity—where excessive muscle loss could worsen balance, fractures and disability.
Measurement remains a key dispute: Ravussin argued DEXA tracks fat-free mass rather than true skeletal muscle, while D3-creatine dilution better predicts poor performance and mortality but is still largely limited to research settings.
Both experts pointed to mitigation rather than abandoning GLP-1s, emphasizing resistance exercise and adequate protein, with Ravussin noting only 20% of patients are prescribed exercise.